• Objective: To investigate the relationship between hyperglycemia and hospital mortality in a heterogeneous group of critically ill patients.
Mechanisms include insulin resistance, absolute or relative insulin deficiency, impaired glucose metabolism, and the effect of medications such as corticosteroids and densely caloric enteral and parenteral nutritional supplements. 1 Although hyperglycemia can be a marker of severity of illness, it also can worsen outcomes. Takala et al 2 reported that growth hormone therapy, which led to hyperglycemia and insulin resistance, was associated with a doubling of the mortality rate of a group of critically ill patients. Hyperglycemia also is associated with poor outcome in both diabetic and nondiabetic patients after stroke. [3] [4] [5] [6] The plasma glucose value on admission has been shown to affect prognosis in a group of nondiabetic patients with acute myocardial infarction. 7 Diabetic patients with myocardial infarction who underwent intensive glycemic management with insulin infusions followed by tightly controlled subcutaneous insulin administration had improved 1-year survival rates compared with a cohort who received standard glycemic management. 8 Similarly, continuous intravenous insulin infusion reduced the rate of sternal wound infections in a group of diabetic patients who underwent cardiac surgery. 2 Finally, Van den Berghe et al 9 recently described a 34% reduction in hospital mortality in a group of 1548 patients in a single surgical critical care unit with use of intensive insulin therapy to achieve euglycemia.
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The relationship between hyperglycemia and outcome in a heterogeneous group of critically ill patients has not been well described. This retrospective review of a large database from a single university-affiliated community hospital was undertaken to examine the effect of hyperglycemia on mortality in a heterogeneous population of critically ill adult patients admitted to an intensive care unit (ICU).
PATIENTS AND METHODS
Between October 1, 1999, and April 4, 2002, 2098 patients were admitted to The Stamford Hospital ICU. If a patient required readmission, only laboratory data and outcomes from the first admission were included. Plasma glucose The diagnostic groups within each patient subgroup are shown in Table 1 . 10 
Databases
We use a comprehensive database to track multiple outcomes for all patients admitted to the ICU. The core dataset is maintained and updated daily by the director of critical care and an associate, who ensure data integrity and completeness. Data included in this report include length of stay (LOS) in 0.1-day increments, Acute Physiology and Chronic Health Evaluation II (APACHE II) score based on the first 24 hours after ICU admission, 11 age, and primary ICU diagnosis. The director of critical care assigns a primary diagnosis at the time of ICU admission on the basis of the 80+ APACHE III diagnostic categories, 12 which are more detailed and numerous than those found in the APACHE II system. A modified APACHE II score is calculated by deleting the age component from the APACHE II score to analyze separately the contributions of acuity of illness and age to mortality. This database is linked to multiple hospital databases with queries, allowing linkage of the central core of information with discharge status, ICD-9 codes assigned at the time of discharge, and laboratory data obtained during the ICU stay.
Measurements
During patients' ICU stay, all plasma glucose values were obtained with use of a query linking the master database to the laboratory database, and the final discharge status for each patient was ascertained. A single value representing the mean of these glucose values was assigned to each patient and correlated with final discharge status. The initial and maximum glucose values obtained during ICU stay also were abstracted from the database for separate analysis. The terms survivor and nonsurvivor relate to hospital discharge status, not ICU discharge status. All plasma glucose assays were performed using Vitros 950 and Vitros 250 chemistry analyzers (Ortho-Clinical Diagnostics, Raritan, NJ, a division of Johnson & Johnson).
Statistical Analyses
Statistical analysis was performed using the SPSS 11.0 statistical package. Glucose values, age, LOS, and APACHE II scores were expressed as mean and range and were compared between survivors and nonsurvivors with use of the Wilcoxon test for populations without normal distribution. Because LOS was measured in 0.1-day increments, the shortest LOS abstracted from the database was 0.0 days (total LOS in the ICU <1 hour). Comparisons of the percentage of patients in different subgroups requiring mechanical ventilation were performed using the χ 2 statistic, which also was used to test for the trend of increasing hospital mortality with increasing mean glucose levels and to assess differences in mortality rates among groups of patients. Multiple stepwise logistic regression analysis was used to assess the effect on hospital mortality of APACHE II scores, APACHE II scores with the age component deleted ("modified APACHE II score"), age, glucose values, need for mechanical ventilation, and LOS. Statistical significance was defined as P<.05; all results were 2-tailed.
The Stamford Hospital Institutional Review Board approved this study.
RESULTS

Baseline Characteristics and Selected Outcomes
Selected characteristics of the 1826 patients and the different subgroups are described in Table 2 . APACHE II scores reflect data obtained during the first 24 hours after admission. A total of 27 patients (1.48%) were between age 13 and 19 years. Patients with septic shock had the highest APACHE II scores and the lowest hospital survival. Patients with pulmonary diseases had the longest ICU LOS and the highest percentage of mechanical ventilation. Sex had no effect on severity-adjusted survival ( Table 3) .
Comparisons of Survivors and Nonsurvivors
Survivors were compared with nonsurvivors for each subgroup and for the entire group (Table 4) . Survivors had lower APACHE II scores than did nonsurvivors in all patient subgroups (P<.001 for all comparisons). Nonsurvivors were older than survivors in all patient subgroups except for the septic shock and trauma subgroups. The percentage of patients requiring mechanical ventilation was significantly greater among nonsurvivors than among survivors in every patient subgroup (P<.001). The mean ICU LOS was significantly greater (P<.001) for nonsurvivors than for survivors in all subgroups except for those in septic shock, neurologic, and trauma subgroups, among whom there was no significant difference.
Glucose Values and Hospital Mortality
The mean of all glucose values obtained during each patient's ICU stay was calculated, and this single value was assigned to each patient, regardless of the number of separate assays obtained. The number of glucose values obtained for each patient correlated significantly with the patient's LOS (R = 0.870; P<.001).
Mean, initial, and maximum glucose values obtained for survivors and nonsurvivors during the ICU stay are compared in Table 5 . Mean and maximum glucose values were significantly higher for nonsurvivors than for survivors for the entire population and for each subgroup except for patients with septic shock. Striking differences in mean glucose values between survivors and nonsurvivors were revealed when results were stratified by age (Table 6 ).
Initial glucose values were significantly higher among nonsurvivors than among survivors for the entire population and for most of the subgroups (Table 5) . Of the 1826 patients whose records were reviewed, 24 (1.31%) had an ICU LOS less than 0.5 day. Among these patients, the 11 survivors had a mean glucose value of 156.9 mg/dL (range, 99.5-342.0 mg/dL), and the 13 nonsurvivors had a mean glucose value of 299.7 mg/dL (range, 74.0-1183.0 mg/dL) (P=.12).
The relationship of hospital mortality to mean serum glucose values obtained during the ICU stay for patients with mean serum glucose values of 80 mg/dL or greater is shown in Table 7 . The lowest hospital mortality, 9.6%, occurred among patients with mean glucose values between 80 and 99 mg/dL. Patients with mean glucose values of 100 to 119 mg/dL, still within the normal range for this laboratory test, had a 27% increase in hospital mortality compared with those with mean glucose values of 80 to 99 mg/dL. Hospital mortality increased progressively with further increases in mean glucose values, with the highest hospital mortality (42.5%) noted among patients with mean glucose values exceeding 300 mg/dL (χ 2 for trend, P<.001). There was a similar relationship between mean plasma glucose and hospital survival for each patient subgroup (χ 2 for trend, P<.001) except for the patients in the pulmonary subgroup. The 35 patients (1.92%) with mean glucose values less than 80 mg/dL had a 22.9% hospital mortality rate.
Relationship of Diabetes to Glucose Values and Hospital Mortality
The presence of diabetes was ascertained using ICD-9 codes assigned at hospital discharge. Diabetes was present in 22.4% of the entire population. The highest prevalence of diabetes was observed in the cardiac subgroup (29.2%), whereas the lowest was seen in the trauma subgroup (5.1%). For the entire group, there was no difference in mortality based on the presence or absence of diabetes. Hospital mortality was higher among diabetic patients in the neurologic subgroup (P<.001) but not statistically different for any of the other groups.
Mean 
Multiple Stepwise Logistic Regression Analysis of Factors Relating to Hospital Mortality and ICU LOS
Results of multiple stepwise logistic regression analyses are presented in Table 9 . A modified APACHE II score, eliminating the age component from the APACHE II calculation, was used to analyze separately the contributions of age and acuity of illness to mortality. Modified APACHE II score, age, mean glucose value, and the need for mechanical ventilation were associated with hospital mortality (R = 0.517, P<.001); the modified APACHE II score contributed the greatest amount to the model. Sex and ICU LOS were not significantly associated with mortality.
Univariate regression revealed that mechanical ventilation (P<.001) and modified APACHE II score (P=.01) were significantly associated with ICU LOS. Mean glucose value, age, and sex were not significantly associated with ICU LOS.
DISCUSSION
The salient finding of this investigation is that even a modest elevation of mean glucose levels occurring during ICU stay was associated with increased hospital mortality in a heterogeneous population of critically ill patients. The retrospective design prevents conclusions regarding whether hyperglycemia was a cause of increased mortality or rather just a marker of increased risk of mortality. Nevertheless, the strong association between hospital mortality and glycemic levels, which has potentially important clinical implications, extended from the entire population through the subgroups. The lowest hospital mortality, 9.6%, occurred among patients with mean glucose values between 80 and 99 mg/dL. Among patients with mean glucose values between 100 and 119 mg/dL, still within the normal range for this laboratory test, mortality increased to 12.2%, representing a 27% relative increase. Further increases in mean glucose had a progressively deleterious association with hospital mortality, culminating in 42.5% hospital mortality among patients with mean glucose values exceeding 300 mg/dL (P<.001 for trend). An analysis of maximum glucose values instead of mean glucose values during ICU stay yielded similar results, but initial glucose levels were somewhat less predictive. Furthermore, analysis of glucose values added predictive power for hospital mortality beyond that achieved by APACHE II scoring alone, a finding not reported previously. Within APACHE II groupings of 0 to 14, 15 to 24, and 25 or greater, glucose values were higher among nonsurvivors than among survivors. Finally, multiple stepwise logistic regression analysis confirmed that increasing APACHE II scores and increasing mean glucose values were independent predictors of hospital mortality.
The main strength of the study is the large number of patients who were evaluated, which provided the opportunity for extensive subgroup analysis. Other strengths include the detailed and accurate diagnostic breakdown and the extensive descriptive data and outcome data available from the linked databases. Moreover, the heterogeneous nature of the population makes the data applicable to other mixed medical-surgical ICU settings. Finally, the data are robust: the difference in mean glucose values between survivors and nonsurvivors was substantial-137.9 mg/dL (range, 54.0-642.3 mg/dL) vs 172.0 mg/dL (range, 27.0-1183.0 mg/dL) (P<.001)-and the large size of the subgroups allowed analysis with confidence.
The main limitation of this study is its retrospective nature. This design prevented uniformity in the collection of serum glucose values for individual patients. The number of glucose values obtained correlated strongly with the patient's LOS in the ICU (R = 0.870; P<.001), and a single value representing the mean of the individual assays was assigned to each patient. Inferences were based on this single mean value, although there were variable numbers of individual tests and indications for obtaining them. A separate analysis of hospital mortality related to maximum glucose value obtained during the ICU stay revealed the same strong relationship; the mean glucose value was chosen as the primary variable instead of the maximum glucose value because the mean value more closely approximated overall glycemic control during ICU stay.
Another limitation was that the diagnosis of diabetes was derived from the ICD-9 codes assigned at hospital discharge by hospital coders. Although it is unlikely that diabetes was diagnosed incorrectly in any patient, some patients who developed hyperglycemia during their ICU stay possibly had latent diabetes that was not correctly designated as such.
Finally, the study period was 30 months, and consecutive admissions were analyzed. Data relating to ICD-9 diagnoses were not available for 128 of the 2098 patients admitted; for an additional 144 patients, no serum glucose values were obtained during their ICU stay. However, if the data from the 128 patients (6.1%) with missing ICD-9 diagnoses had been included, it probably would not have altered the main findings of the study.
Other investigators have noted that hyperglycemia is a marker of poor outcome in specific clinical contexts. A substantial body of evidence supports this association among patients with neurologic disease. Young et al 5 described the relationship between hyperglycemia at admis- Finally, Demchuk et al 13 found that hyperglycemia predicted the development of intracerebral hemorrhage after thrombolytic therapy for ischemic stroke. Hyperglycemia also has been implicated as a predictor of worsened outcome in cardiac surgery patients. Fietsam et al 14 reported increased wound infection, arrhythmia, and respiratory failure among 146 diabetic patients compared with 565 nondiabetic patients who underwent coronary artery bypass grafting surgery. Mean glucose values among the diabetic patients who had postoperative complications in this series exceed those of the diabetic patients without complications. Glucose values for the nondiabetic patients were not reported.
Several investigators have evaluated the role of intensive glycemic management in different patient populations. Perioperative glucose values and sternal wound infection rates were significantly lower among 1499 diabetic patients who underwent cardiac surgery and were treated with continuous insulin infusions compared with 968 diabetic patients who underwent similar surgery and received standard subcutaneous insulin on the basis of a sliding-scale protocol. 15 Similarly, 620 diabetic patients with acute myocardial infarction were randomized to insulin infusion followed by intensive subcutaneous insulin administration vs standard care (the Diabetes Mellitus, Insulin Glucose Infusion in Acute Myocardial Infarction [DIGAMI] study). 8 Plasma glucose values obtained during hospitalization were significantly lower in the treatment group than in the control group, and the 1-year mortality rates were 18.6% and 26.1%, respectively (29% relative mortality reduction; P=.03). More recently, Van den Berghe et al 9 reported their investigation of intensive glucose control in a group of patients requiring mechanical ventilation in the surgical ICU for more than 5 days. They used insulin infusions if needed in the treatment arm to achieve glucose levels between 80 and 110 mg/dL. The ICU mortality rate decreased from 8.0% to 4.6%, and the patients treated in the ICU had a significant decrease in the requirement for hemodialysis and blood transfusions and a reduction in the incidence of critical-illness polyneuropathy.
CONCLUSION
This investigation showed that even a modest degree of hyperglycemia occurring during ICU stay was associated with increased hospital mortality in a heterogeneous group of critically ill patients. Hospital mortality was lowest among patients with mean serum glucose values between 80 and 99 mg/dL and increased significantly and progressively as mean serum glucose values exceeded this range. Analysis of maximum glucose values obtained during each patient's ICU stay revealed the same association. The differences in mean glucose values between survivors and nonsurvivors were greater among nondiabetic patients than among diabetic patients. These differences occurred at significantly lower mean glucose values among the nondiabetic patients than among the diabetic patients.
Multiple stepwise logistic regression analysis confirmed that hyperglycemia was an independent risk factor for increased hospital mortality. Even among patients with similar APACHE II scores, the mean glucose values were higher in nonsurvivors than among survivors, suggesting that the measurement of serum glucose values provided additional discriminative power to this standard mortality prediction model. Although this investigation was not designed to assess whether hyperglycemia was a cause of increased hospital mortality or just an epiphenomenon, these findings provide a compelling justification for conducting trials of intensive glycemic management in a heterogeneous population of critically ill patients.
I thank Noel Robin, MD, and Dominic Roca, MD, PhD, for their thoughtful review of the submitted manuscript. I also thank Paul Sachs, MD, for his steadfast assistance in maintaining the ICU database.
